Literature DB >> 11854648

Elevated amniotic fluid C-reactive protein at the time of genetic amniocentesis is a marker for preterm delivery.

Fabio Ghezzi1, Massimo Franchi, Luigi Raio, Edoardo Di Naro, Giuseppina Bossi, Gian Vico Melzi D'Eril, Pierfrancesco Bolis.   

Abstract

OBJECTIVE: A pre-existing intrauterine inflammation in the first half of gestation has been proposed as a possible condition that leads to preterm delivery. Indeed, elevated levels of inflammatory mediators (eg, interleukin-6, tumor necrosis factor) in midtrimester amniotic fluid have been found in cases of preterm delivery and/or spontaneous abortion. The objective of this study was to investigate whether the amniotic fluid C-reactive protein level at the time of genetic amniocentesis is a marker for spontaneous preterm delivery before 34 and 37 weeks of gestation. STUDY
DESIGN: Women who underwent genetic amniocentesis between 15 and 18 weeks of gestation with (1) singleton gestation, (2) uneventful pregnancy course before the amniocentesis, and (3) absence of fetal abnormalities were included in the study. Patients with abnormal karyotype were excluded. C-reactive protein concentration was measured in amniotic fluid and in maternal blood immediately after genetic amniocentesis. All patients were followed until delivery for the occurrence of pregnancy complications. Nonparametric tests and receiver-operating characteristic curve analysis were used for statistical purposes.
RESULTS: The prevalence of spontaneous preterm delivery before 34 and 37 weeks was 3.3% (10 of 306 pregnancies) and 8.5% (26 of 306 pregnancies), respectively. Women with preterm delivery at <37 weeks had a higher median (range) of amniotic fluid C-reactive protein concentration than those women who delivered at term (median, 113.3 ng/mL [range, 16-623 ng/mL] vs median, 57.8 ng/mL [range, 0-808.9 ng/mL]; P <.005). Women with preterm delivery at <34 weeks had a higher median (range) amniotic fluid C-reactive protein concentration than those women who delivered at term (median, 183.8 ng/mL [range, 46.5-447 ng/mL] vs median, 57.8 ng/mL [range, 0-808.9 ng/mL]; P <.005]. No correlation was found between amniotic fluid C-reactive protein and maternal blood C-reactive protein concentrations. No relationship was found between maternal blood C-reactive protein concentration and preterm delivery before either 34 or 37 weeks. Amniotic fluid C-reactive protein concentration of >110 ng/mL had a sensitivity of 80.8% and a specificity of 69.5% in the prediction of spontaneous preterm delivery at <34 weeks.
CONCLUSION: This study supports the theory that a subclinical intrauterine/fetal inflammatory process early in gestation may be important for the occurrence of preterm delivery in the second half of gestation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854648     DOI: 10.1067/mob.2002.119628

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

1.  Phospholipid scramblase expression in the pregnant mouse uterus in LPS-induced preterm delivery.

Authors:  Kelley C McLean; Karen H Oppenheimer; Leigh M Sweet; Mark Phillippe
Journal:  Reprod Sci       Date:  2012-05-17       Impact factor: 3.060

2.  Can maternal serum C-reactive protein levels predict successful labour induction with intravenous oxytocin in term pregnancies complicated with premature rupture of the membranes? A cross-sectional study.

Authors:  Serkan Kahyaoğlu; Hakan Timur; Remzi Eren; Inci Kahyaoğlu; Elif Gül Yapar Eyi; Yaprak Engin-Üstün
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-03-01

3.  Cardiovascular Disease-Related Pregnancy Complications Are Associated with Increased Maternal Levels and Trajectories of Cardiovascular Disease Biomarkers During and After Pregnancy.

Authors:  Nisha I Parikh; Barbara Laria; Gregory Nah; Meghali Singhal; Eric Vittinghoff; Cassandra Vieten; Naomi Stotland; Kimberly Coleman-Phox; Nancy Adler; Michelle A Albert; Elissa Epel
Journal:  J Womens Health (Larchmt)       Date:  2020-01-14       Impact factor: 2.681

4.  Maternal serum interleukin-6, C-reactive protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth <32 weeks and adverse neonatal outcomes.

Authors:  Yoram Sorokin; Roberto Romero; Lisa Mele; Ronald J Wapner; Jay D Iams; Donald J Dudley; Catherine Y Spong; Alan M Peaceman; Kenneth J Leveno; Margaret Harper; Steve N Caritis; Menachem Miodovnik; Brian M Mercer; John M Thorp; Mary Jo O'Sullivan; Susan M Ramin; Marshall W Carpenter; Dwight J Rouse; Baha Sibai
Journal:  Am J Perinatol       Date:  2010-03-01       Impact factor: 1.862

5.  Plasma C-reactive protein in early pregnancy and preterm delivery.

Authors:  Waranuch Pitiphat; Matthew W Gillman; Kaumudi J Joshipura; Paige L Williams; Chester W Douglass; Janet W Rich-Edwards
Journal:  Am J Epidemiol       Date:  2005-10-19       Impact factor: 4.897

6.  Maternal serum C-reactive protein concentrations in early pregnancy and subsequent risk of preterm delivery.

Authors:  Vitool Lohsoonthorn; Chunfang Qiu; Michelle A Williams
Journal:  Clin Biochem       Date:  2007-01-05       Impact factor: 3.281

7.  Usefulness of marking alkaline phosphatase and C-reactive protein in monitoring the risk of preterm delivery.

Authors:  Hubert Huras; Piotr Ossowski; Robert Jach; Alfred Reron
Journal:  Med Sci Monit       Date:  2011-11

8.  Causes of adverse pregnancy outcomes and the role of maternal periodontal status - a review of the literature.

Authors:  Jagan Kumar Baskaradoss; Amrita Geevarghese; Abdullah Al Farraj Al Dosari
Journal:  Open Dent J       Date:  2012-05-09

9.  Applying Maternal Serum and Amniotic Fluid CRP Concentrations, and Cervical Length to Predict Preterm Delivery.

Authors:  Sedigheh Borna; Masoomeh Mirzamoradi; Alireza Abdollahi; Foruzan Milani; Parichehr Pouransari
Journal:  J Family Reprod Health       Date:  2013-03

10.  Maternal serum interleukin 6 and 8 and C-reactive protein in predicting the tocolytic therapy in preterm labor.

Authors:  Zahra Shahshahan; Leila Hashemi; Ousha Rasouli
Journal:  J Res Med Sci       Date:  2014-06       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.